What are the limitations of the aa ipi score?

While the aa ipi score is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the aa ipi score to ensure safe bedside use and optimal diagnostic accuracy.

How does the aa ipi score compare to other Hematology scores?

The aa ipi score is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the aa ipi score free to use?

Yes. OpiCalc provides the aa ipi score completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

935 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

aaIPI (Age-adjusted IPI)

Age-Adjusted IPI: Calculated for patients ≤ 60 years. Age is excluded as a variable to highlight biological lymphoma risk.

aaIPI Prediction (≤ 60yr)

0

Risk Category

Low

Estimated 5-y Overall Survival: 83%

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic stratification of younger patients (≤ 60 years) with aggressive Non-Hodgkin Lymphoma (NHL).

To guide treatment intensity in patients where age is not a limiting factor for intensive therapy.

Standard trial stratification for "young/fit" cohorts.

Patient Population

Patients ≤ 60 years old with Diffuse Large B-cell Lymphoma (DLBCL) or other aggressive NHL.

When Not to Rely on This Score Alone

Patients > 60 years — use the standard IPI or NCCN-IPI.

Follicular Lymphoma — use FLIPI or FLIPI-2.

Section 2

Formula & Logic

Scoring Variables (+1 point each)

Serum LDH > Upper Limit of Normal

ECOG Performance Status ≥ 2

Ann Arbor Stage III or IV

Risk Groups

Score	Risk Group	Estimated 5-y OS
0	Low	83%
1	Low-Intermediate	69%
2	High-Intermediate	46%
3	High	32%

Section 3

Pearls/Pitfalls

Focus on Biology

By removing the "Age" variable, the aaIPI focuses more purely on the biological aggressiveness of the lymphoma (Stage, LDH) and the patient's compensation (Status).

Section 4

Evidence Appraisal

Primary Score

A predictive model for aggressive non-Hodgkin's lymphoma.

Solal-Celigny P et al. • New England Journal of Medicine. 1993;329(14):987-94. (Age-adjusted analysis section)

View Source

Section 5

Literature

Development

Extracted from the original IPI dataset to address the need for a system that better differentiates risk in younger populations where age itself does not drive mortality.

Last Comprehensive Review: 2026

Related Hematology Tools

DIPSS-Plus

MIPSS70+ v2.0

JAK2V617F Allele Burden Interpreter

Sokal/EUTOS/ELTS Comparison

Have feedback about this calculator?Let us know.